Skip to main content
. 2022 Nov 11;119(46):e2203491119. doi: 10.1073/pnas.2203491119

Table 2.

Genes with excess DNV burden in DD versus ASD patients

Gene DD DNV (dnLGD/dnMIS) ASD DNV (dnLGD/dnMIS) P q OR (95% CI) Significant variant
ARID1B 119 (106/13) 22 (12/10) 2.51e–6 5.02e–3 2.7 (1.7–4.5) DNV&dnLGD
DDX3X 115 (50/65) 5 (1/4) 5.41e–15 1.08e–10 11.6 (4.8–36.3) DNV&dnLGD&dnMIS
KMT2A 90 (64/26) 9 (6/3) 2.25e–8 1.50e–4 5 (2.5–11.3) DNV&dnLGD
DYRK1A 80 (64/16) 4 (4/0) 3.11e–10 3.11e–6 10 (3.8–37.8) DNV&dnLGD
MED13L 72 (42/30) 10 (5/5) 1.71e–5 2.14e–2 3.6 (1.9–7.9) DNV
SATB2 68 (32/36) 5 (0/5) 1.31e–7 4.37e–4 6.8 (2.8–21.7) DNV&dnLGD
STXBP1 67 (28/39) 8 (3/5) 7.10e–6 1.18e–2 4.2 (1–10.1) DNV
CTNNB1 62 (60/2) 5 (4/1) 7.84e–7 1.74e–3 6.2 (2.5–19.8) DNV&dnLGD
TCF4 51 (31/20) 4 (3/1) 9.21e–6 1.42e–2 6.4 (2.4–24.4) DNV
KMT2D 47 (30/17) 3 (0/3) 6.63e–6 1.18e–2 7.9 (2.5–39.5) DNV&dnLGD
KCNQ2 45 (0/45) 1 (0/1) 3.01e–7 8.61e–4 22.6 (3.9–907.9) DNV&dnMIS
CACNA1A 43 (3/40) 1 (0/1) 5.05e–7 1.26e–3 21.6 (3.7–868.6) DNV&dnMIS
EFTUD2 43 (31/12) 3 (1/2) 2.67e–5 3.14e–2 7.2 (2.3–36.2) DNV
WDR45 35 (24/11) 1 (1/0) 1.06e–5 1.51e–2 17.6 (3–710.9) DNV
CASK 34 (24/10) 1 (1/0) 1.71e–5 2.14e–2 17.1 (2.9–691.2) DNV
GATAD2B 42 (39/3) 0 (0/0) 5.52e–8 2.21e–4 Inf (5.5–Inf) DNV&dnLGD
KIF1A 42 (0/42) 0 (0/0) 5.52e–8 2.21e–4 Inf (5.5–Inf) DNV&dnMIS
CHD7 51 (31/20) 6 (0/6) 7.36e–6 1.64e–2 Inf (4–Inf) dnLGD only

Two-sided Fisher’s exact test for DNV counts was performed comparing ASD (n = 15,560) and DD (n = 31,052) patients. This table shows the 18 genes with significant DNV burden in DD compared to ASD patients, while no gene with significant burden is identified in ASD patients. The significance threshold (FDR 5%) was corrected for 20,000 genes (Benjamini-Hochberg). OR: odds ratio; CI: confidence interval; Inf: infinity.